Welcome!

Cognitive Computing Authors: Yeshim Deniz, Elizabeth White, Liz McMillan, Pat Romanski, Zakia Bouachraoui

News Feed Item

Immunotech Laboratories Inc. Announces Clinical Trials Updates For Company's AIDS-HIV "IPF" Medicines

PASADENA, Calif., Feb. 20, 2013 /PRNewswire/ -- Immunotech Laboratories, Inc. (PINKSHEETS: IMMB) Today announced the following updates for the International Clinical Trials of the company's patented AIDS-HIV "IPF" Medicine(s).

Immunotech Founder and President Harry Zhabilov today announced the progress with the project IPF-ITV-1 in the European Union. Mr. Zhabilov stated: "We have negotiated with two of the biggest hospitals in Bulgaria (thus, European Union) to carry our clinical trials of IPF-ITV-1 and ITV-2 as follows:

At the Infectious Disease Hospital, Sofia, with Hospital Director Prof. Cherveniakova we will carry out clinical trials of ITV-1 with 50 patients infected with HIV-AIDS in its most advanced stage.

At the Military Hospital, Sofia, with Hospital Director Prof. General Stoyan Tonev we will carry out clinical trials of ITV-2 with 50 patients ill with chronic hepatitis in its most advanced stage." The clinical trials will be conducted parallel with protease inhibitor.

Mr. Zhabilov further stated: "We believe that in both cases, the results will be very good, because in Bulgaria until this point, we have already applied the experimental labeled "IPF" Medicine with HIV infected volunteers and the outcomes to date have been extremely successful."

Immunotech recently completed negotiations in the Republic of Macedonia with Bionika Pharmaceuticals who agreed to carry out clinical trials of IPF-ITV-3 with 50 patients ill with HCV using the "IPF" labeled Experimental Drug Medicines.

The clinical trials in Bulgaria (Referred to as, EU) are scheduled to begin in March 2013 and end in August 2013, which will give Immunotech, the rights to receive approval for huge applications of the "IPF" Medicines. In this respect, Immunotech has had a series of conversations with Mr. Vladimir Stoichev, the Deputy General Director from Sopharma Bulgaria, and the parties have reached agreement for the signing of a contract between Immunotech Laboratories BG and Sopharma for joint production of IPF-ITV.

Sopharma is a leading pharmaceutical company in the European Union.

RELEVANT ARTICLES & LINKS FOR AIDS-HIV MEDICINES

http://news.yahoo.com/gsk-wins-priority-status-hiv-drug-u-161639474--finance.html

About Immunotech Laboratories
Immunotech Laboratories is a drug development company committed to the commercialization of its proprietary proteins for the treatment of debilitating infectious diseases such as HIV, Cancer, Hepatitis and Aids. www.immunotechlab.com

Safe Harbor Statement: This news release contains forward-looking statements that involve risks and uncertainties associated with financial projections, budgets, milestone timelines, clinical development, regulatory approvals, and other risks described by Immunotech Laboratories, Inc. from time to time in its periodic reports filed with the SEC. IPF is not approved by the US Food and Drug Administration or by any comparable regulatory agencies elsewhere in the world. While Immunotech Laboratories believes that the forward-looking statements and underlying assumptions contained therein are reasonable, any of the assumptions could be inaccurate, including, but not limited to, the ability of Immunotech Laboratories to establish the efficacy of IPF in the treatment of any disease or health condition, the development of studies and strategies leading to commercialization of IPF in the United States, the obtaining of funding required to carry out the development plan, the completion of studies and tests on time or at all, and the successful outcome of such studies or tests. Therefore, there can be no assurance that the forward-looking statements included in this release will prove to be accurate. In light of the significant uncertainties inherent in the forward-looking statements included herein, Immunotech Laboratories or any other person that the objectives and plans of Immunotech Laboratories will be achieved should not regard the forward-looking statements as a representation.

Company Contact: [email protected]

Investor Relations:
The Nabors Group: 713-875-9200
E-mail: [email protected]
www.facebook.com/Naborsgroup

SOURCE Immunotech Laboratories, Inc.

More Stories By PR Newswire

Copyright © 2007 PR Newswire. All rights reserved. Republication or redistribution of PRNewswire content is expressly prohibited without the prior written consent of PRNewswire. PRNewswire shall not be liable for any errors or delays in the content, or for any actions taken in reliance thereon.

IoT & Smart Cities Stories
To Really Work for Enterprises, MultiCloud Adoption Requires Far Better and Inclusive Cloud Monitoring and Cost Management … But How? Overwhelmingly, even as enterprises have adopted cloud computing and are expanding to multi-cloud computing, IT leaders remain concerned about how to monitor, manage and control costs across hybrid and multi-cloud deployments. It’s clear that traditional IT monitoring and management approaches, designed after all for on-premises data centers, are falling short in ...
The deluge of IoT sensor data collected from connected devices and the powerful AI required to make that data actionable are giving rise to a hybrid ecosystem in which cloud, on-prem and edge processes become interweaved. Attendees will learn how emerging composable infrastructure solutions deliver the adaptive architecture needed to manage this new data reality. Machine learning algorithms can better anticipate data storms and automate resources to support surges, including fully scalable GPU-c...
A valuable conference experience generates new contacts, sales leads, potential strategic partners and potential investors; helps gather competitive intelligence and even provides inspiration for new products and services. Conference Guru works with conference organizers to pass great deals to great conferences, helping you discover new conferences and increase your return on investment.
Poor data quality and analytics drive down business value. In fact, Gartner estimated that the average financial impact of poor data quality on organizations is $9.7 million per year. But bad data is much more than a cost center. By eroding trust in information, analytics and the business decisions based on these, it is a serious impediment to digital transformation.
SYS-CON Events announced today that Silicon India has been named “Media Sponsor” of SYS-CON's 21st International Cloud Expo, which will take place on Oct 31 – Nov 2, 2017, at the Santa Clara Convention Center in Santa Clara, CA. Published in Silicon Valley, Silicon India magazine is the premiere platform for CIOs to discuss their innovative enterprise solutions and allows IT vendors to learn about new solutions that can help grow their business.
We are seeing a major migration of enterprises applications to the cloud. As cloud and business use of real time applications accelerate, legacy networks are no longer able to architecturally support cloud adoption and deliver the performance and security required by highly distributed enterprises. These outdated solutions have become more costly and complicated to implement, install, manage, and maintain.SD-WAN offers unlimited capabilities for accessing the benefits of the cloud and Internet. ...
SYS-CON Events announced today that CrowdReviews.com has been named “Media Sponsor” of SYS-CON's 22nd International Cloud Expo, which will take place on June 5–7, 2018, at the Javits Center in New York City, NY. CrowdReviews.com is a transparent online platform for determining which products and services are the best based on the opinion of the crowd. The crowd consists of Internet users that have experienced products and services first-hand and have an interest in letting other potential buye...
Business professionals no longer wonder if they'll migrate to the cloud; it's now a matter of when. The cloud environment has proved to be a major force in transitioning to an agile business model that enables quick decisions and fast implementation that solidify customer relationships. And when the cloud is combined with the power of cognitive computing, it drives innovation and transformation that achieves astounding competitive advantage.
Founded in 2000, Chetu Inc. is a global provider of customized software development solutions and IT staff augmentation services for software technology providers. By providing clients with unparalleled niche technology expertise and industry experience, Chetu has become the premiere long-term, back-end software development partner for start-ups, SMBs, and Fortune 500 companies. Chetu is headquartered in Plantation, Florida, with thirteen offices throughout the U.S. and abroad.
DXWorldEXPO LLC announced today that "IoT Now" was named media sponsor of CloudEXPO | DXWorldEXPO 2018 New York, which will take place on November 11-13, 2018 in New York City, NY. IoT Now explores the evolving opportunities and challenges facing CSPs, and it passes on some lessons learned from those who have taken the first steps in next-gen IoT services.